<a href="https://www.fiercebiotech.com/biotech/sarepta-shares-positive-safety-update-dm1-asset-arrowhead-hits-200m-milestone" hreflang="en">Sarepta shares positive safety update on DM1 asset as Arrowhead snares $200M milestone</a>

A drug safety group has delivered a positive analysis for a Sarepta-licensed RNA medicine, with the same study also hitting an enrollment target. The latter development has triggered a $200 milestone payment due to Arrowhead Pharmaceuticals.